The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
about
Haloperidol versus placebo for schizophreniaAntipsychotic medication for early episode schizophreniaRisperidone versus placebo for schizophreniaHaloperidol versus placebo for schizophreniaOlanzapine for schizophreniaThe influence of atypical antipsychotic drugs on sexual functionAntipsychotic-induced hyperprolactinemiaOlanzapine for schizophrenia.Haloperidol versus placebo for schizophrenia.The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Management of and counseling for psychotropic drug-induced sexual dysfunction.Body weight gain induced by antipsychotic drugs: mechanisms and management.Risk of osteoporosis and fracture incidence in patients on antipsychotic medication.Ziprasidone, a new atypical antipsychotic drug.Breast enlargement associated with low dose olanzapinePharmacological causes of hyperprolactinemiaTreating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).Antipsychotics: impact on prolactin levels.Antipsychotic-induced sexual dysfunction and its managementA review of the association between antipsychotic use and hyperprolactinaemia.Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder.Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents.Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone.The Effects of Antipsychotics on Prolactin Levels and Women's Menstruation.Sex steroids and schizophrenia.Drug review "surprises" readerAntipsychotic induced hyperprolactinaemia: a series of illustrative case reports.Olanzapine-induced galactorrhea.Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine.Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.Risperidone versus placebo for schizophreniamGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind TrialRelationship Between Plasma Levels of Prolactin and the Severity of Negative Symptoms in Patients with Schizophrenia
P2860
Q24202457-D031965B-007B-422B-AF85-32755A487C3CQ24236683-FCB3EC7D-4719-4909-B5B3-26DFAC3642ACQ24241041-8D756E92-7904-4D0B-B5CB-D1F704ADC435Q24243823-B3092262-319F-4F7D-8D90-FA843C6F041EQ24244031-BFB874E4-8A1E-41E2-B660-6129BB90BF8AQ26799708-BDB07557-009D-4E4F-ACE8-FF4E10128A50Q28305237-ADA609A3-A02C-4A1E-8D02-6CAFF4AAC98EQ30868034-6FF73683-1271-44EE-88C3-907B7DD44773Q30992683-3F285ACA-909F-4F81-BC3B-A64BB64DD967Q33395073-751AF555-1FAD-4558-9565-782DB0F6CC42Q33619940-08AA2EAC-6A7E-4F7E-AEAA-FC61A707C1E7Q33693819-4CFD15E2-5CA9-447D-B0CD-FF44E3599623Q33708467-64C1CDEA-4E99-42BB-97E6-864A11159A1CQ34026011-F9D22D8C-04FF-40E6-99BA-0F12FA91D0AAQ34278844-2A6C6730-9BFF-4D1F-8D56-C31C14AEC3F0Q34706526-F178B9D7-13A5-45B4-85E6-94B7E4F0025FQ34778045-03F9ABD0-01C6-4416-BECA-4F878EA48617Q34966395-10DD097F-6EDE-4F9D-BBAD-04270D67FBA7Q34974785-2F6B929A-15CC-4BAE-B6F4-1F4188272696Q36758151-0C8F7F98-2462-4CEF-AB34-96F4AF15CE5AQ37162798-127ACE0D-5A25-4F97-A8B4-EAF206279B58Q37162812-27487EE3-41F3-4E20-B94E-27C6B7F1A546Q37172865-BFC5CE55-A83F-462C-840F-062D9BD32EB5Q37224571-8EC5F658-8A1A-49E7-8CD3-F4E99808262EQ37456024-AD77230F-54DD-4ADC-B7ED-CF6AAF095A5CQ37878384-C100E05E-0022-4944-95C8-6691B42C565AQ42848375-98AE419F-8418-4E11-98F0-0BD47FF74493Q43841264-4FCBDE8E-1E6C-4F5E-9894-8568417CF955Q44078945-0F657138-76DB-4944-B9A4-187AAF0F5075Q44212820-81BB235A-54AF-4491-BD10-426BC9F1D2D1Q44983975-CBF85437-EE37-4383-A139-6DF7C8B4C0EBQ45052993-601077FC-8D06-4365-AAC0-230AB9BB6150Q46200033-A8F7A8CF-EACF-4D25-B6B5-79157C12218AQ55894951-71C6084D-CF47-479A-92F3-272AD99E1ADDQ57665054-2FE0D11C-B5E4-4603-8B7E-18E97C16EA1EQ57820223-55961619-E7B5-4CDC-A22A-4D5B4C124DB1
P2860
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
The acute and long-term effect ...... erum prolactin concentrations.
@en
The acute and long-term effect ...... erum prolactin concentrations.
@nl
type
label
The acute and long-term effect ...... erum prolactin concentrations.
@en
The acute and long-term effect ...... erum prolactin concentrations.
@nl
prefLabel
The acute and long-term effect ...... erum prolactin concentrations.
@en
The acute and long-term effect ...... erum prolactin concentrations.
@nl
P2093
P1476
The acute and long-term effect ...... erum prolactin concentrations.
@en
P2093
A M Crawford
C M Beasley
G D Tollefson
P356
10.1016/S0920-9964(97)00036-4
P407
P577
1997-07-01T00:00:00Z